2
Views
0
CrossRef citations to date
0
Altmetric
Original Article

Does Treatment Present Material Risks?

Pages 61-70 | Published online: 08 Jul 2009
 

Abstract

The safety of anti-secretory treatment can only be confirmed by extensive use, although animal studies, human pharmacological investigations, and examination of outcome in controlled trials form essential preliminaries. The interpretation is, however, hindered by the confounding influence of disease present before treatment started, owing to coincident disease. Careful analysis of data is required to demonstrate this phenomenon, which is a major factor impeding the demonstration of drug-induced illness, which mimics ordinary disease. So far a substantial body of data which covers an extensive time after initial drug use has only been collected for cimetidine. This gives reassurance about drug safety during ordinary use, but confirms the difficulty caused by confounding. Studies of other drugs must take the same problems into account during interpretation.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.